On October 9, 2018 BerGenBio ASA (OSE:BGBIO) reported that the company and its collaborators will present interim clinical and biomarker data from its Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor at the ESMO (Free ESMO Whitepaper) 2018 Congress in Munich (19 – 23 October 2018) (Press release, BerGenBio, OCT 9, 2018, View Source [SID1234529835]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pre-clinical data on the role of AXL inhibition in Myelodysplastic Syndrome (MDS) will also be presented. Details of the presentations are below.
The posters will be made available at www.bergenbio.com in the Investors / Presentations section at the time of presentation and full abstracts will be made available online according to ESMO (Free ESMO Whitepaper)’s embargo schedule: View Source
Poster presentations at ESMO (Free ESMO Whitepaper):
Sunday 21 October, 11:15 – 12:15, Hall B3 – Room 21
Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials
Robert Holt, PhD et al
Poster Discussion session – Translational research 2
Invited discussant: 11:15 – 11:45
Presentation number: 63PD
Sunday 21 October, 12:45 – 13:45, Hall A3 – Poster Area
Update on the randomised Phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma
Cornelia Schuster, MD, PhD et al
Poster display session – Melanoma and other skin tumours
Presentation number: 1266P
Sunday 21 October, 16:30 – 17:45, Hall B3 – Room 21
The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS
Hind Medyouf, PhD et al
Poster Discussion session – Haematological malignancies
Invited discussant: 16:30 – 16:55
Presentation number: 1009PD
END
About the ESMO (Free ESMO Whitepaper) Congress
The ESMO (Free ESMO Whitepaper) Congress is the leading European meeting for medical oncology convening over 20,000 international delegates from the field. ESMO (Free ESMO Whitepaper) 2018 will be held in Munich, Germany 19-23 October 2018.